Smoking is one of the risk factors for lung cancer, and most male lung cancer patients have a history of smoking and most female patients have a history of secondhand smoke exposure. Therefore, most patients are able to quit smoking after lung cancer diagnosis. However, there are still a few patients who smoke in small amounts after the treatment process. It has been shown that smoking decreases the blood levels of certain drugs and therefore affects their efficacy. To address the reality that a small number of patients still smoke without interruption, an international multicenter clinical study was conducted to provide more appropriate treatment for this group of patients. Enrollment: Patients with non-small cell lung cancer who have failed first-line chemotherapy and are still smoking Treatment regimen: Troche 150mg vs. Troche 300mg If eligible for enrollment, the drug is provided free of charge.